Biothorpe Pharmaceuticals is a biotechnology company focused on the development of siRNA, oligonucleotides and other molecular technologies for the treatment of cancer.
Biothorpe’s intellectual property portfolio, which is exclusively licensed from its parent company, ZaBeCor Pharmaceuticals, includes the worldwide rights to the following drug candidates:
| Drug Candidate Name | Type of Technology | Potential Use/Indication |
| Rebelex™ | siRNA / oligonucleotides directed at Syk kinase | Acute Myelogenous Leukemia |
| Lymphozene™ | siRNA / oligonucleotides directed at Syk kinase | B-Cell Lymphoma |
| Leukozene™ | siRNA / oligonucleotides directed at Syk kinase | Chronic Lymphocytic Leukemia |